Trial Profile
Effect of Pioglitazone on Tissue Inhibitor of Metalloproteinases 3 (TIMP-3) and TNF (Tumor Necrosis Factor)-α Converting Enzyme (TACE) in Skeletal Muscle and Their Circulating Substrates
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms PIO-TACE
- 27 Sep 2013 Results in skeletal muscle presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 30 Jun 2013 Results published in the Diabetologia.
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.